SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2018.01.085
Abstract: BACKGROUND Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SGLT-2i) had lower rates of death and heart failure (HF). Whether the benefits of SGLT-2i vary based upon the presence of cardiovascular disease (CVD) is… read more here.
Keywords: risk; death; sglt; cvd real ... See more keywords